Gabriel Galvão Rafael Magalhães
Research Subjects
Gabriel Galvão Rafael Magalhães has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bernardo Matos da Cunha
Hospital Sarah, Brasília
1 shared publication - Bruno Silva de Araujo Ferreira
Centro Universitário Serra dos Órgãos (UNIFESO), Teresopolis, RJ, Brazil
1 shared publication - Cristiane da Fonseca Hottz
Rede SARAH Hosp Reabilitacao, Ambulatorio Osteometabol, Brasilia, DF, Brazil
1 shared publication - Frederico Gideoni Albinati Batista
Rede SARAH Hosp Reabilitacao, Ambulatorio Osteometabol, Brasilia, DF, Brazil
1 shared publication - Larissa Aniceto Moreira
Department of Internal Medicine-Rheumatology, SARAH Network of Rehabilitation Hospitals , Brasília, Brazil
1 shared publication - Luciana Pinto Valadares
Unit of Osteometabolic Disorders, SARAH Network of Rehabilitation Hospitals, Brasília, Brazil
1 shared publication
Latest Publications
- Open Access
- 19 April 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 247-255
Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience
Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with [...] ABSTRACT Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with
- 19 April 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 247-255
Open AccessEffects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience
Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with [...] ABSTRACT Objective: Fibrous dysplasia (FD) is a rare bone disorder that can involve any part of the skeleton, leading to bone pain, deformities, and fractures. Treatment with intravenous bisphosphonates has been used with variable results. Therefore, we aimed to evaluate the effects of zoledronic acid (ZA) therapy in patients with monostotic or polyostotic FD. Subjects and methods: The medical records of thirteen patients with FD evaluated between 2015 and 2020 were retrospectively analyzed. In the subgroup of patients treated with